MicroPort® MedBot™'s Investigational Toumai® System Used in First Robotic Telesurgery Between Two U.S. Hospitals Under FDA IDE Study.
ORLANDO, FL, October 28, 2026 — MicroPort® MedBot™ today announced that its Toumai® surgical robotic system, which is investigational in the United States, was used on October 25 in a robotic radical prostatectomy connecting two hospitals in Florida, approximately 35 miles apart. This was the first robotic telesurgery performed in the United States, according to the Society of Robotic Surgery (SRS).1
The procedure was conducted as part of a clinical study under an Investigational Device Exemption (IDE) approved by the U.S. Food and Drug Administration (FDA). The IDE authorizes the clinical investigation.*
Dr. Vipul Patel, founder and medical director of the Global Robotics Institute at AdventHealth Celebration and principal investigator of the study, operated the investigational Toumai® system remotely from AdventHealth Celebration. Co-principal investigator Dr. Marcio Moschovas and the bedside surgical team supported the patient at AdventHealth Minneola, with the ability to intervene if needed.
The procedure was completed in 103 minutes. The study team observed no interruptions in robotic control and reported clear two-way audio communication throughout. Study data remain under evaluation.
This Florida procedure is part of the same FDA-approved IDE study that previously included 10 investigational telesurgery procedures between Orlando and Luanda, Angola, beginning in June 2025. The study has now extended to procedures between two U.S. hospitals.
“For generations, access to highly specialized care has often depended on where a patient lives,” Dr. Patel said in a statement published by AdventHealth. “This study allows us to evaluate whether telesurgery could one day help reduce geographic barriers to specialized treatment. Important questions about safety, effectiveness and technical performance remain under investigation.”2
MicroPort® MedBot™’s approach to innovation begins with the needs of patients and the healthcare professionals who care for them. Its telesurgery research program explores whether technology could one day bring surgical expertise closer to patients.
About MicroPort® MedBot™
Commenced development of laparoscopic surgical robots in 2014 and officially established in Shanghai in 2015, Shanghai MicroPort MedBot (Group) Co., Ltd. ("MicroPort® MedBot™", stock code: 02252.HK), a subsidiary of MicroPort Scientific Corporation ("MicroPort®", stock code: 00853.HK), Its surgical robotics portfolio spans five major segments: laparoscopic, orthopedic, vascular interventional, natural orifice, and percutaneous surgical robotics.
MicroPort® MedBot™ integrates robotics, intelligent control, image-guided navigation, and precision imaging technologies to develop intelligent surgical solutions that support minimally invasive care worldwide.
*Regulatory Status
MicroPort MedBot has obtained FDA approval of an IDE to study the Toumai® system in the United States. The Toumai® system has not received FDA clearance or approval for commercial distribution in the U.S. market. The IDE does not establish that the system is safe or effective; it only permits the device to be studied in a clinical investigation under FDA oversight.
CAUTION: Investigational device. Limited by United States law to investigational use.
References
- Society of Robotic Surgery. Breaking News: First Robotic Telesurgery in the United States. October 26, 2026. https://srobotics.org/breaking-news-first-robotic-telesurgery-in-the-united-states/
- AdventHealth. Historic study explores whether robotic telesurgery could bring specialized surgical care closer to home. October 26, 2026. https://www.adventhealth.com/news/historic-study-explores-whether-robotic-telesurgery-could-bring-specialized-surgical-care-closer
MicroPort Forward-Looking Statements
For purposes of this statement, "MicroPort" refers to MicroPort Scientific Corporation (HKEX: 00853) and, where the context requires, one or more of its direct and indirect subsidiaries, affiliates, and other entities under its control, including the business units and operations referenced in this press release. Statements in this press release concerning associated companies, joint ventures or third-party partners are based on information available to MicroPort and should not be interpreted as statements made by, or on behalf of, those entities.
This press release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and include, among other things, statements regarding the development, clinical evaluation, regulatory review and approval, commercialization and market adoption of MicroPort products and technologies; anticipated clinical, operational or commercial benefits; market opportunities; business and geographic expansion; and MicroPort's strategies, plans, objectives, expectations, projections and estimates. Such statements may be identified by words such as "expects," "anticipates," "believes," "intends," "estimates," "plans," "projects," "may," "will," "could," and similar expressions.
Forward-looking statements are based on current expectations, assumptions and information available as of the date of this press release and are subject to known and unknown risks and uncertainties, many of which may be difficult to predict or beyond MicroPort's control. These may include, among others: the outcomes and timing of research and development activities, clinical studies and regulatory processes, including submissions, reviews, decisions and the obtaining, maintenance, expansion or renewal of approvals, clearances and registrations, product safety, quality, recalls or manufacturing issues, product liability claims, changes in laws, regulations, healthcare, pricing and procurement policies (including centralized or volume-based procurement programs) or reimbursement environments, market acceptance, competition, pricing pressure, and commercial performance, supply-chain disruptions and dependence on suppliers, distributors, collaboration partners and other third parties, the ability to obtain, maintain and enforce intellectual property rights, as well as intellectual property matters, disputes or litigation, cybersecurity, information security and data protection risks, compliance with applicable anti-corruption, export control, sanctions and healthcare industry laws and regulations, access to financing, currency fluctuations, tariffs, trade restrictions and other international trade measures, and general economic, industry, market or geopolitical conditions.
For additional information regarding risks and uncertainties, readers should refer to the annual and interim reports and other public disclosures of MicroPort Scientific Corporation and, where applicable, any listed subsidiary whose securities are publicly traded.
Actual results may differ materially from those expressed or implied in any forward-looking statement. There can be no assurance that products or technologies under development will successfully complete clinical evaluation, obtain or maintain regulatory approvals, clearances or registrations in any particular jurisdiction, be commercialized within anticipated timelines or at all, or achieve anticipated clinical or commercial outcomes.
Forward-looking statements speak only as of the date of this press release and are based on the assumptions and information available as of such date. In light of the risks, uncertainties and assumptions described above, readers are cautioned not to place undue reliance on such statements. Except as required by the SFO, the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, or any other applicable law or regulation, MicroPort undertakes no obligation to publicly update or revise any forward-looking statement to reflect new information, future events or otherwise.